Tissue Engineered Veins in Patients With Chronic Venous Insufficiency

• Status: Not yet recruiting
• Trial end date: 2023-10-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the safety (incidence of adverse events including serious adverse events and clinical significant laboratory abnormalities) of personalized tissue engineered veins (P-TEV) with valves implanted in patients with severe chronic venous insufficiency (CVI). For each patient a segment of the femoral vein containing the non-functioning valve will be surgically replaced with a single P-TEV containing a functioning valve.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Verigraft AB

Criteria

Inclusion Criteria:

• Patients aged between 18 and 65 years (inclusive)

• CVI patients with skin changes and/or recurrent leg ulcer despite optimal conservative treatment for a period of time according to the investigator's judgement

• Patients with deep venous reflux (grade 4)

• Anesthesiologically cleared and meeting ASA (American Society of Anesthesiologists Classification) class 1 or 2

• Laboratory values

• INR <1.7 (in case the patient uses Orfarin, the test might be repeated after the anticoagulant change)

• Platelets ≥ 100 x 10 9 /L

• Hemoglobin ≥ 100 g/L

• Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

• ASAT ≤ 2.5 × ULN

• ALAT ≤ 2.5 × ULN

• Lipid profile within acceptable range according to investigator's opinion

• Clinical chemistries (K, Ca) within acceptable range according to Investigator's opinion

• Ability to understand the requirements of the study, provide written informed consent, and comply with the study procedures

Exclusion Criteria:

• Patients incapable to give written informed consent

• Patients unlikely to cooperate fully in the study and/or with an anticipated poor compliance

• Non-walking patients or patients with lost ankle joint function

• Patients previously organ-transplanted

• Patients with cancer except in-situ stage cancer (basal-cell carcinomas and/or cervix cancer) and five year recurrence free period after treatment

• Patients with autoimmune diseases including rheumatoid arthritis, SLE and MS

• Pregnant or breast feeding women

• Patients with ongoing estrogen treatment/contraception. (intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence should be used for contraception by women of childbearing period).

• BMI ≥ 35

• Patients who participate in other clinical trials

• Patients with artery pathology (ankle-brachial pressure index < 0,9 or > 1,3)

• Patients with thrombophilia according to the laboratory results at inclusion visit. One of the following criteria is needed for thrombophilia: Protein C < 40% or Protein S < 40 % or Leiden factor mutation or Antithrombin III < 40 % or present Lupus anticoagulant or Homocysteine > 1.5 ULN

• Patients with an active infection requiring systemic antibiotic treatment

• Patients with clinically significant cardiac disease (New York Heart Association, Class III or IV) or measured LVEF 40%

• Patients with uncontrolled hypertension

• Patients with renal dysfunction eGFR < 45 ml/min (according to the MDRD calculation)

• Patients with moderate or severe hepatic impairment (Child Pugh ≥ 7 points, i.e. class B or C)

• Patients with ongoing immunosuppression, Cortisol treatment etc.

• Less than 3 months since previous ipsilateral venous intervention (e.g. Iliac recanalization)

• Clinically significant outflow disease

• Heavy smoker: Has smoked 20 cigarettes or more per day for at least past 5 years

• Other uncontrolled intercurrent illness that would jeopardize the patient's safety, interfere with the objectives of the protocol, or limit the patient's compliance with study requirements, as determined by the investigator in consultation with the sponsor